Strategic partnerships There is a recent collaboration with Daiichi Sankyo to develop next-generation predictive biomarkers in an ADC clinical development program, signaling a path to co-development opportunities and potential multi-year commercial engagements.

Industry networking High-visibility partnerships with Oracle and AMD to scale predictive oncology indicate a strong ecosystem approach, presenting entry points for joint go-to-market efforts, data integration pilots, and enhanced credibility with large biopharma customers.

Clinical to commercial Q-Plasia OncoReader offers a unique capability to predict therapy response from routine biopsy images, creating a compelling value proposition for pharma and contract research organizations seeking precision treatment workflows and faster patient stratification.

Funding signal Recent strategic financing and board additions suggest investor confidence and potential for accelerated commercialization, enabling sales teams to pursue larger partnership deals, pilots, and expanded customer footprint.

Scale readiness Engagement with industry giants and cloud/AI infrastructure partners implies readiness to scale deployments; focus sales efforts on oncology centers, biopharma ADC programs, and analytics-driven CROs that need scalable predictive biomarkers.